Article
Document
Academic Article
Information Content Entity
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
Generically Dependent Continuant
RDF description of Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study - http://irises.unibs.it/resource/item/175559